Repligen Corp (RGEN) stock
RGENNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 30, 2026Score 7/30132% above fair value
$162.18−0.60 (-0.37%)
Close on Nov 17, 2026Market cap $10.37BP/E –Yield –
Repligen total assets
Total assets on the balance sheet at the end of each period.
Repligen's total assets was $2.93B at Sep 30, 2026. For fiscal 2025 it was $2.95B, up 4.2% from the year before. Over ten years it grew 35.0% a year on average. The highest annual figure on record is $2.95B in fiscal 2025.
Annual total assets
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $2.95B | +4.2% |
| FY2024 | Dec 31, 2024 | $2.83B | -0.1% |
| FY2023 | Dec 31, 2023 | $2.83B | +11.8% |
| FY2022 | Dec 31, 2022 | $2.53B | +7.3% |
| FY2021 | Dec 31, 2021 | $2.36B | +23.9% |
| FY2020 | Dec 31, 2020 | $1.90B | +35.9% |
| FY2019 | Dec 31, 2019 | $1.40B | +80.7% |
| FY2018 | Dec 31, 2018 | $774.62M | +4.2% |
| FY2017 | Dec 31, 2017 | $743.52M | +157.4% |
| FY2016 | Dec 31, 2016 | $288.91M | +97.6% |
| FY2015 | Dec 31, 2015 | $146.24M | +14.0% |
| FY2014 | Dec 31, 2014 | $128.29M | +8.1% |
| FY2013 | Dec 31, 2013 | $118.64M | +64.1% |
| FY2011 | Mar 31, 2011 | $72.29M | – |
Quarterly total assets
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $2.93B | +0.1% |
| Q2 FY2026 | Jun 30, 2026 | $2.95B | +1.7% |
| Q1 FY2026 | Mar 31, 2026 | $2.93B | +2.8% |
| Q4 FY2025 | Dec 31, 2025 | $2.95B | +4.2% |
| Q3 FY2025 | Sep 30, 2025 | $2.92B | +3.3% |
| Q2 FY2025 | Jun 30, 2025 | $2.90B | +1.2% |
| Q1 FY2025 | Mar 31, 2025 | $2.85B | -0.1% |
| Q4 FY2024 | Dec 31, 2024 | $2.83B | -0.1% |
| Q3 FY2024 | Sep 30, 2024 | $2.83B | +12.2% |
| Q2 FY2024 | Jun 30, 2024 | $2.87B | +12.1% |
| Q1 FY2024 | Mar 31, 2024 | $2.85B | +12.0% |
| Q4 FY2023 | Dec 31, 2023 | $2.83B | +11.8% |
| Q3 FY2023 | Sep 30, 2023 | $2.52B | +2.4% |
| Q2 FY2023 | Jun 30, 2023 | $2.56B | +4.6% |
| Q1 FY2023 | Mar 31, 2023 | $2.55B | +6.9% |
| Q4 FY2022 | Dec 31, 2022 | $2.53B | +7.3% |
| Q3 FY2022 | Sep 30, 2022 | $2.46B | +9.9% |
| Q2 FY2022 | Jun 30, 2022 | $2.44B | +21.3% |
| Q1 FY2022 | Mar 31, 2022 | $2.38B | +23.7% |
| Q4 FY2021 | Dec 31, 2021 | $2.36B | +23.9% |
| Q3 FY2021 | Sep 30, 2021 | $2.24B | +51.8% |
| Q2 FY2021 | Jun 30, 2021 | $2.02B | +39.8% |
| Q1 FY2021 | Mar 31, 2021 | $1.93B | +37.0% |
| Q4 FY2020 | Dec 31, 2020 | $1.90B | +35.9% |
| Q3 FY2020 | Sep 30, 2020 | $1.48B | +7.1% |
| Q2 FY2020 | Jun 30, 2020 | $1.44B | +35.0% |
| Q1 FY2020 | Mar 31, 2020 | $1.41B | +76.3% |
| Q4 FY2019 | Dec 31, 2019 | $1.40B | +80.7% |
| Q3 FY2019 | Sep 30, 2019 | $1.38B | +80.9% |
| Q2 FY2019 | Jun 30, 2019 | $1.07B | +43.4% |
| Q1 FY2019 | Mar 31, 2019 | $797.92M | +7.4% |
| Q4 FY2018 | Dec 31, 2018 | $774.62M | +4.2% |
| Q3 FY2018 | Sep 30, 2018 | $762.13M | +3.8% |
| Q2 FY2018 | Jun 30, 2018 | $745.08M | +141.3% |
| Q1 FY2018 | Mar 31, 2018 | $743.25M | +155.7% |
| Q4 FY2017 | Dec 31, 2017 | $743.52M | +157.4% |
| Q3 FY2017 | Sep 30, 2017 | $734.24M | – |
| Q2 FY2017 | Jun 30, 2017 | $308.76M | – |
| Q1 FY2017 | Mar 31, 2017 | $290.63M | – |
| Q4 FY2016 | Dec 31, 2016 | $288.91M | – |
See a number that looks wrong?